The National Healthcare Security Administration (NHSA) of China, in conjunction with the Supreme People’s Court, the Supreme People’s Procuratorate, the Ministry of Public Security, the Ministry of Finance, and the National Health Commission, has unveiled the “2024 Special Work Plan for the Rectification of Illegal and Non-compliant Issues Related to Medical Insurance Funds.” This initiative mandates that all provinces, municipalities, and autonomous regions conduct a thorough rectification of legal and regulatory compliance within the medical insurance sector and take stringent measures against fraud.
The rectification efforts will specifically target fraudulent practices, including false diagnosis and treatment, the falsification of drug purchases, and the resale of drugs listed in the National Reimbursement Drug List (NRDL). The plan will prioritize the monitoring of key drugs and medical consumables that have seen significant medical insurance fund expenditure and exhibit unusual patterns, employing dynamic oversight of fund utilization. Furthermore, the initiative will emphasize the convergence of rectification with treatment, necessitating a sweeping self-assessment and corrective action in critical areas such as orthopedics, hemodialysis, cardiovascular care, diagnostic services, laboratory testing, and rehabilitation therapy. – Flcube.com
